• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Nepal Journal of Epidemiology >Efficacy of Statins in Dyslipidemia: A Non interventional comparative study in a tertiary care hospital, Ajman, UAE
【24h】

Efficacy of Statins in Dyslipidemia: A Non interventional comparative study in a tertiary care hospital, Ajman, UAE

机译：他汀类药物在血脂异常中的功效：阿联酋阿治曼市三级医院的非干预性比较研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BackgroundThe reduction of serum total cholesterol and LDL-cholesterol levels varies with different statins. The objective of the present study was to compare the efficacy of Simvastatin, Atorvastatin and Rosuvastatin in the treatment of newly diagnosed dyslipidemia.Material and Methods:A prospective, non-interventional 12-week study was conducted after approval from the Ethics Committee. A total of 70 patients with newly diagnosed dyslipidemia receiving 20mg of Simvastatin, Atorvastatin or Rosuvastatin were included. The primary efficacy measure was reduction of lipid levels from the initial baseline values at the end of 12 weeks with the respective Statins. Data was analyzed using descriptive statistics, Paired -t test, and analysis of variance (ANOVA).Results:Of total 70 patients, 14 patients received Simvastatin; 40 patients received Atorvastatin and 16 patients received Rosuvastatin. Demographic and baseline clinical characteristics were similar between the three groups. Significant reduction in lipid levels (total cholesterol, and LDL) was seen within the three treatment groups (p<0.01). However, statistically significant difference in the reduction lipid levels was not observed between the three groups.Conclusion:We found no significant difference in the reduction of lipid levels between Simvastatin, Atorvastatin or Rosuvastatin patients with newly diagnosed dyslipidemia.DOI: http://dx.doi.org/10.3126je.v4i5.12023 Nepal Journal of Epidemiology 2014; 4(5):428-32
机译：背景血清总胆固醇和LDL-胆固醇水平的降低因他汀类药物的不同而不同。本研究的目的是比较辛伐他汀，阿托伐他汀和瑞舒伐他汀在新诊断的血脂异常中的疗效。材料与方法：经伦理委员会批准，进行了一项为期12周的前瞻性，非干预性研究。总共包括70名新诊断为血脂异常的患者，接受20mg辛伐他汀，阿托伐他汀或瑞舒伐他汀治疗。主要功效指标是使用各自的他汀类药物在12周后将脂质水平从初始基线值降低。结果：在70例患者中，有14例接受了辛伐他汀治疗;其中70例患者接受了辛伐他汀治疗。 40例患者接受了阿托伐他汀，16例患者接受了瑞舒伐他汀。三组之间的人口统计学和基线临床特征相似。在三个治疗组中均观察到血脂水平（总胆固醇和LDL）显着降低（p <0.01）。然而，三组之间未观察到血脂降低水平的统计学差异。结论：我们发现辛伐他汀，阿托伐他汀或瑞舒伐他汀新诊断为血脂异常患者之间的血脂降低水平没有显着差异.DOI：http：// dx .doi.org / 10.3126 / nje.v4i5.12023尼泊尔流行病学杂志2014; 4（5）：428-32

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号